CSL Limited (CSLLY)
OTHER OTC:CSLLY
Top Page
CSL
(OTC:CSLLY)
Select Model
Select Model
Rating:76Outperform
Price Target:
$28.00
▼(-52.08% Downside)
Action:ReiteratedDate:02/11/26
The score is driven primarily by strong financial performance (profitability and cash flow) and supportive technical momentum. This is tempered by a mixed earnings call with meaningful near-term headwinds and only moderate valuation support.
Positive Factors
Cash generation
Strong operating and free cash flow provide durable internal funding for R&D, capacity investment and shareholder returns. Consistent cash conversion reduces refinancing risk, supports the expanded buyback program and dividend continuity, and underpins long‑term strategic optionality.
Negative Factors
Large impairments & restructuring
Material impairment and restructuring charges reduce reported earnings and introduce near‑term volatility in returns metrics. They signal either asset underperformance or strategic repositioning, creating execution risk on realizing forecasted cost savings and complicating year‑over‑year comparability for investors.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Strong operating and free cash flow provide durable internal funding for R&D, capacity investment and shareholder returns. Consistent cash conversion reduces refinancing risk, supports the expanded buyback program and dividend continuity, and underpins long‑term strategic optionality.
Read all positive factors
CSL (CSLLY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$48.17B
Dividend Yield2.33%
Average Volume (3M)1.91K
Price to Earnings (P/E)69.3
Beta (1Y)0.40
Revenue Growth5.08%
EPS Growth13.41%
CountryUS
Employees32,698
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.21
Shares Outstanding1,941,275,900
10 Day Avg. Volume0
30 Day Avg. Volume1,912
Financial Highlights & Ratios
PEG Ratio3.83
Price to Book (P/B)7.93
Price to Sales (P/S)9.94
P/FCF Ratio60.28
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue3.81
Enterprise Value/Gross Profit7.83
Enterprise Value/Ebitda11.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CSL Business Overview & Revenue Model
Company Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two ...
How the Company Makes Money
CSL makes money primarily by selling biopharmaceutical products and related services through its operating businesses. A major revenue stream is plasma-derived therapies: via its plasma collection network, the company collects human plasma, fracti...
CSL Earnings Call Summary
Earnings Call Date:Feb 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Neutral
The call presented a mixed picture: solid cash generation, strong specialty product launches (HEMGENIX, ANDEMBRY), Seqirus market-share gains and meaningful progress on a large transformation program were balanced against meaningful near-term headwinds — including revenue declines, large noncash impairments (~$1.1bn), product and market-specific pressures (Ig Medicare Part D impact, albumin policy impact in China, iron generics, and impending reimbursement changes for Velphoro). Management maintained guidance, expanded capital returns, and outlined concrete remediation actions, but several challenges will weigh on reported earnings in the near term.Positive Updates
Strong cash generation and capital returns
Operating cash flow of $1.3 billion in H1; leverage reduced to ~2x; expanded share buyback program from $500 million to $750 million after repurchasing ~USD 400 million in the half; interim dividend maintained at USD 1.30.
Negative Updates
Group revenue and reported earnings decline
Group revenue of $8.3 billion was down 4% (constant currency) and NPATA fell 7%; reported net profit after tax declined 81% after one-off restructuring and impairment charges.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong cash generation and capital returns
Operating cash flow of $1.3 billion in H1; leverage reduced to ~2x; expanded share buyback program from $500 million to $750 million after repurchasing ~USD 400 million in the half; interim dividend maintained at USD 1.30.
Read all positive updates
Company Guidance
CSL confirmed it is maintaining full‑year guidance while outlining the key drivers and metrics: H1 group revenue US$8.3bn (‑4% cc), gross profit US$4.6bn (‑3%), group operating result US$3.8bn (‑4%), NPATA before restructuring and impairments US$1.9bn (‑7%) and reported NPAT down 81% after ~US$1.05bn of H1 impairments (total FY26 after‑tax impairments ~US$1.1bn with ~US$70m H2 expected); operating cash flow was US$1.3bn and an interim dividend of US$1.30 was declared; balance sheet leverage ~2x at Dec‑2025 after ~US$400m of buybacks and the buyback program expanded from US$500m to US$750m. Management expects double‑digit H2 growth in Ig (PRIVIGEN/HIZENTRA), albumin in China to stabilise (modest FY26 decline with a return to growth in FY27), Seqirus to lap seasonality in a global market down mid‑ to high‑single digits, and Vifor to see strong nephrology growth (+12% H1) but continued iron pressure and Injectafer LOE in FY27. Cost and margin actions include H1 R&D US$600m (‑8%) with similar spend forecast in H2 and a VarmX candidate entering Phase III in H2, G&A down 2% and expected flat in H2, a FY26 cost‑save target of US$100m (60% achieved at H1) on the way to up to US$550m p.a. by FY28 against one‑off restructuring costs of US$700–770m, an underlying H1 tax rate ~21% with FY26 expected 18–20%, and continued focus on driving profit and cash conversion to support reinvestment and returns.CSL Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.56B | 15.43B | 14.80B | 13.17B | 10.49B | 10.27B |
| Gross Profit | 7.56B | 7.95B | 7.56B | 6.71B | 5.66B | 5.74B |
| EBITDA | 5.09B | 5.13B | 4.73B | 3.90B | 3.46B | 3.63B |
| Net Income | 1.43B | 3.00B | 2.64B | 2.19B | 2.25B | 1.78B |
Balance Sheet | ||||||
| Total Assets | 37.90B | 39.40B | 38.02B | 36.23B | 28.35B | 13.63B |
| Cash, Cash Equivalents and Short-Term Investments | 1.15B | 2.16B | 1.66B | 1.55B | 10.44B | 1.36B |
| Total Debt | 12.57B | 11.50B | 12.18B | 12.23B | 9.66B | 4.36B |
| Total Liabilities | 17.44B | 18.00B | 18.62B | 18.41B | 13.77B | 7.34B |
| Stockholders Equity | 18.66B | 19.34B | 17.36B | 15.79B | 14.58B | 6.29B |
Cash Flow | ||||||
| Free Cash Flow | 3.16B | 2.54B | 1.51B | 909.00M | 1.38B | 2.43B |
| Operating Cash Flow | 3.74B | 3.56B | 2.76B | 2.60B | 2.63B | 3.62B |
| Investing Cash Flow | -1.17B | -850.00M | -1.26B | -11.84B | -1.64B | -1.67B |
| Financing Cash Flow | -3.01B | -2.24B | -1.28B | 456.00M | 7.68B | -1.40B |
CSL Technical Analysis
Neutral
58.43
Price Trends
26.51
Negative
27.84
Negative
31.92
Negative
Market Momentum
-0.46
Negative
50.78
Neutral
46.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSLLY, the sentiment is Neutral. The current price of 58.43 is above the 20-day moving average (MA) of 24.54, above the 50-day MA of 26.51, and above the 200-day MA of 31.92, indicating a neutral trend. The MACD of -0.46 indicates Negative momentum. The RSI at 50.78 is Neutral, neither overbought nor oversold. The STOCH value of 46.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CSLLY.
CSL Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $81.16B | 17.92 | 14.83% | 0.45% | 2.89% | 0.50% | |
76 Outperform | $48.17B | 69.34 | 7.56% | 2.33% | 5.08% | 13.41% | |
75 Outperform | $48.96B | 14.76 | 16.82% | ― | 89.58% | ― | |
72 Outperform | $113.50B | 29.32 | 22.70% | ― | 10.53% | ― | |
57 Neutral | $42.61B | 166.04 | 90.35% | ― | 53.24% | ― | |
54 Neutral | $23.12B | -17.95 | -6.03% | ― | 7.04% | -25.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CSLLY
CSL
24.75
-12.15
-32.92%
ALNY
Alnylam Pharma
321.28
95.00
41.98%
REGN
Regeneron
767.85
224.43
41.30%
VRTX
Vertex Pharmaceuticals
446.78
-28.71
-6.04%
ARGX
Argenx Se
800.50
254.28
46.55%
BNTX
BioNTech SE
91.98
-1.14
-1.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.